WILLIAM A. BLATTNER, M.D.; ROBERT J. BIGGAR, M.D.; STANLEY H. WEISS, M.D.; MADS MELBYE, M.D.; JAMES J. GOEDERT, M.D.
The discovery of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) has opened a window to the understanding of the spectrum of the acquired immunodeficiency syndrome (AIDS) and related clinical syndromes. Analysis of risk factors for seropositivity has shown that HTLV-III is transmitted most efficiently via routes that involve close personal contact or parenteral exposure. Longitudinal studies have shown that HTLV-III infection has a long latent period. The prevalence of AIDS in different geographic areas and among different risk groups appears to depend in part on duration of exposure. Co-factors for AIDS outcome such as manner and route of exposure, underlying immune status, and host susceptibility are also likely to play a role in risk.
BLATTNER WA, BIGGAR RJ, WEISS SH, et al. Epidemiology of Human T-Lymphotropic Virus Type III and the Risk of the Acquired Immunodeficiency Syndrome. Ann Intern Med. 1985;103:665–670. doi: https://doi.org/10.7326/0003-4819-103-5-665
Download citation file:
Published: Ann Intern Med. 1985;103(5):665-670.
HIV, Infectious Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use